A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

Inclusion Criteria: * 18 years or older, either gender, and any race. * Psoriasis affecting \>=5% of body surface, PASI score \>=10 (maximum score 72). * History of plaque psoriasis for \>6 months. * Informed written consent. * Refractory to other anti-psoriasis agents (topical corticosteroids, phototherapy UVa \[PUVA\], or systemic therapy). * Negative chest x-ray and purified protein derivative (PPD) within 1 month. * Understand and be able to adhere to dosing and visit schedules. * Screening laboratory tests must meet protocol-specified criteria. * Women and men of childbearing potential must be using adequate birth control measures and should continue such precautions for 6 months after last infusion of infliximab. Exclusion Criteria: * Pregnant, nursing, or planned pregnancy within 6 months after last scheduled treatment. * Used topical corticosteroids in previous 14 days or systemic therapy (phototherapy UVb \[UVB\], PUVA, cyclosporine, methotrexate) in previous 28 days, or received treatment with anti-tumor necrosis factor (TNF)-alpha monoclonal antibodies, human or murine immunoglobulins, TNF-alpha receptor fusion proteins, or other bioengineered fusion proteins. * Received previous immunobiologics. * Have HIV, hepatitis B or C. * Recently transplanted (exception - corneal transplant \>3 months prior to first infusion) or known malignancy or history of malignancy within previous 5 years (exception - basal or squamous cell carcinoma of skin that has been treated with no evidence of recurrence). * Concurrent medications that are not permitted. * congestive heart failure (CHF) * Use of cyclosporine or tacrolimus within 4 weeks prior to Screening. * Use of intramuscular (IM), intravenous (IV), or oral corticosteroids within 4 weeks prior to Screening. * Treatment with any investigational drug within 3 months prior to Screening. * Allergy to murine proteins. * Serious infections (hepatitis, pneumonia, pyelonephritis) in previous 3 months. * History of active tuberculosis (TB) requiring treatment within previous 3 years, or history of opportunistic infections (herpes zoster) within 2 months of Screening. * Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease. * Current signs or symptoms of other severe uncontrolled disease which in investigator's opinion would put the subject at an unacceptable risk. * History of current alcohol or drug abuse. * Not observed designated washout periods for any of the prohibited medications in protocol.